tobramycin inhalation

ApprovedSmall molecule

Novartis

tobramycin inhalation is one of 68 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Cystic FibrosisActive, not recruiting

PneumoniaApproved

Active, not recruiting

Cystic FibrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

tobramycin inhalation

Novartis

Approved

1 2

Primaquine

Sanofi

Preclinical

1 3

Acanya

Pfizer

Preclinical

1 4

Prevacid

Takeda

Preclinical

1 5

Avlosulfon

AAlmirall, S.A.

Preclinical

4 6

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Advil

KKenvue Brands

Preclinical

2 8

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 10

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis4 trials

Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

Completed·MMedical Center Alkmaar·Phase 2/3·NCT02657473·58 enrolled

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

Completed· Novartis logo

Novartis·Phase 3·NCT00388505·517 enrolled

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Terminated· Novartis logo

Novartis·Phase 3·NCT00125346·98 enrolled

Show 1 more trial

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Completed· Gilead logo

Gilead·Phase 3·NCT00757237·274 enrolled

Pseudomonas Aeruginosa1 trial

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Completed· Gilead logo

Gilead·Phase 3·NCT01641822·107 enrolled

ESS1 trial

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

Completed· Novartis logo

Novartis·Phase 3·NCT00918957·62 enrolled

CLE1 trial

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Terminated· Novartis logo

Novartis·Phase 4·NCT02015663·32 enrolled

Pneumonia1 trial

Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia

Completed·EErasmus Medical Center·Phase 4·NCT02440828·80 enrolled

2 more indications

Cystic Fibrosis Lung1 trial

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection

Completed·RRespirion Pharmaceuticals Pty Ltd·Preclinical·NCT06016088·71 enrolled

Unspecified4 trials

Second Open Label Extension to Bridging Study CTBM100C2303

Completed· Novartis logo

Novartis·Phase 3·NCT01069705·49 enrolled

Open Label Extension to Bridging Study CTBM100C2303

Completed· Novartis logo

Novartis·Phase 3·NCT00982930·55 enrolled

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Completed· Novartis logo

Novartis·Phase 4·NCT01844778·60 enrolled

Show 1 more trial

A Study of the Clinical Benefit of Tobramycin Inhalation Solution

Active, not recruiting·QQianfoshan Hospital··NCT06106789·1,600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for tobramycin inhalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tobramycin inhalation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tobramycin inhalation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

tobramycin inhalation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis4 trials

Pseudomonas Aeruginosa1 trial

ESS1 trial

CLE1 trial

Pneumonia1 trial

Cystic Fibrosis Lung1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News